Physician profile
Fred Grunseid
NPI 1023036613
$11,035.28
in general payments reported to CMS, 2019-2025
48 companies · $1,180 in 2025
The $1,180 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,251 · 2020: $1,838 · 2021: $2,061 · 2022: $1,554 · 2023: $1,052 · 2024: $1,099 · 2025: $1,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,330.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $893.36 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $846.43 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $831.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $810.08 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $809.22 | 2019-2022 | |
| Glaxosmithkline, LLC. | $767.87 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $720.62 | 2019-2025 | Verquvo, Gardasil 9, Gardasil |
| Arbor Pharmaceuticals, INC. | $628.28 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $573.37 | 2019-2022 | |
| Pfizer INC. | $368.55 | 2019-2025 | |
| Amgen INC. | $344.55 | 2019-2025 | Repatha, Otezla |
| Amarin Pharma, INC. | $327.46 | 2019-2021 | |
| Esperion Therapeutics, INC. | $261.39 | 2020-2025 | Nexletol |
| Astellas Pharma US INC | $261.08 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $242.94 | 2019-2024 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Grunseid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.